IQV stock forecast, quote, news & analysis
Iqvia is a global leader in clinical research and technology solutions for the life science industry... Show more
IQVIA Holdings (IQV) Stock Analysis: Bracing for Earnings Amid Sharp Pullback
Key Takeaways
- IQV stock has declined about 30% year-to-date, trading near the lower end of its 52-week range of $134.65–$247.05.
- Q1 2026 earnings due May 5, with consensus expecting EPS of $2.82–$2.87 and revenue around $4.1 billion.
- Recent AI initiatives, including IQVIA.ai launch with NVIDIA, highlight technology integration efforts.
- Analyst consensus remains a Buy, with an average price target near $230, suggesting significant upside potential.
- Full-year 2026 revenue guidance projects $17.15–$17.35 billion, supporting long-term growth in healthcare analytics.
- Investors should watch global medicine spending trends and R&D outsourcing demand.
Current Market Snapshot
In recent weeks, IQVIA Holdings (IQV) stock has faced heightened volatility, posting a notable pullback from earlier peaks amid broader market pressures and sector-specific caution. Trading around $158, the shares reflect investor hesitation ahead of quarterly results and ongoing macroeconomic headwinds affecting healthcare services. Despite the downturn, core fundamentals appear resilient, bolstered by steady revenue streams from clinical research and analytics services. Sentiment has shifted due to valuation concerns and competitive dynamics, yet analyst support underscores potential recovery if execution aligns with expectations. Volume has been moderate, signaling a consolidation phase in the latest market cycle.
Trending AI Robots
Tickeron features hundreds of AI Trading Bots that leverage machine learning to trade thousands of tickers across diverse strategies, timeframes, and market conditions—from short-term scalping on 5-minute charts to longer-term trend following over weeks. The curated Trending AI Robots page spotlights the top performers best suited to prevailing volatility and sector rotations. These bots boast impressive stats, including annualized returns ranging from +23% to +163%, win rates of 51%–88%, profit factors up to 11.70, and profit-to-drawdown ratios as high as 17.02. Examples target hot areas like semiconductors (e.g., NVDA, AMD), data centers, and small caps, using AI/ML single or multi-agent approaches with take-profit/stop-loss corridors. With varying risk profiles and no minimum balances for signal agents, they offer accessible tools for enhancing portfolios—explore the page to identify bots aligning with your trading style.
Recent Developments Driving IQV Price Action
IQVIA Holdings (IQV), a leading provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, has seen its stock undergo a sharp decline in recent weeks, dropping roughly 18% from mid-April highs around $180 to current levels near $158. This pullback aligns with broader market selloffs, including pressures from geopolitical tensions and rising oil prices impacting healthcare equities.
A key focus has been anticipation surrounding Q1 2026 earnings, scheduled for release before the market opens on May 5, 2026. Analysts project EPS of approximately $2.82–$2.87 and revenue of $4.1 billion, reflecting steady demand for IQVIA's research organization (RO) services and technology offerings. The company announced the date on April 15, heightening pre-earnings positioning amid mixed signals from prior quarters.
Positive momentum emerged from the April 15 launch of IQVIA.ai in partnership with NVIDIA, aiming to accelerate AI-driven drug discovery and analytics. This initiative has drawn attention to IQVIA's technology segment, potentially offsetting concerns over AI disruption in traditional CRO (contract research organization) models. However, some reports noted AI-related fears contributing to selling pressure despite in-line prior results.
Analyst actions added to the volatility. On April 8, Evercore ISI maintained an Outperform rating but trimmed its price target to $185 from $225, citing valuation adjustments. Around April 21, Citigroup lowered its target to $200 from $230 while keeping a Buy. RBC Capital reaffirmed a Buy on April 15. Consensus remains bullish, with 27 analysts averaging a $230 target, implying over 45% upside.
Shareholders approved a new 2026 Incentive and Stock Award Plan around April 23–24, supporting executive alignment but drawing limited market reaction amid the 8.3% single-day drop on April 23. Broader healthcare sector weakness, including peers like Eli Lilly's competitive developments in obesity treatments, amplified the downside. IQVIA's high debt-to-equity ratio (246%) and elevated beta (1.15–1.18) have amplified sensitivity to risk-off moves.
Overall, price action reflects earnings caution, analyst tweaks, and macro headwinds, tempered by AI tailwinds and robust guidance from February's Q4 report.
2026 Outlook and Key Factors to Monitor
As IQVIA navigates 2026, its full-year revenue guidance of $17.15–$17.35 billion underscores confidence in sustained growth from analytics, real-world evidence, and contract research segments. The IQVIA Institute forecasts global medicine use expanding at 5–8% CAGR through 2030, driven by innovative therapies in oncology and immunology, bolstering demand for IQVIA's data and trial services.
Opportunities lie in AI integration via platforms like IQVIA.ai, enhancing efficiency in drug development amid a robust obesity pipeline exceeding 190 assets. R&D outsourcing trends favor large CROs like IQVIA, with potential tailwinds from regulatory approvals and biopharma M&As (mergers and acquisitions).
Risks include pricing pressures, policy uncertainties in major markets, and elevated leverage amid high interest rates. Competitive positioning against firms like Labcorp and competitive tech shifts warrant scrutiny. Investors should track quarterly execution, technology adoption rates, client retention in RO services, and macroeconomic influences on healthcare spending. Balanced cost management and free cash flow generation (recently $2.22 billion TTM) will be pivotal for shareholder returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
IQV in upward trend: price rose above 50-day moving average on May 28, 2026
IQV moved above its 50-day moving average on May 28, 2026 date and that indicates a change from a downward trend to an upward trend. In of 27 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on May 28, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for IQV crossed bullishly above the 50-day moving average on May 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 218 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where IQV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IQV as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IQV broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IQV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.869) is normal, around the industry mean (12.220). P/E Ratio (22.542) is within average values for comparable stocks, (140.216). Projected Growth (PEG Ratio) (0.731) is also within normal values, averaging (1.506). IQV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (1.872) is also within normal values, averaging (7.227).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties